Example of Breast Cancer Research format
Recent searches

Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format Example of Breast Cancer Research format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Breast Cancer Research — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Oncology #47 of 340 down down by 23 ranks
Cancer Research #46 of 207 down down by 25 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 540 Published Papers | 4745 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 08/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Nature

Quality:  
High
CiteRatio: 16.0
SJR: 4.539
SNIP: 2.28
open access Open Access
recommended Recommended

American Association for Cancer Research

Quality:  
High
CiteRatio: 15.8
SJR: 4.103
SNIP: 1.983
open access Open Access
recommended Recommended

American Association for Cancer Research

Quality:  
High
CiteRatio: 18.2
SJR: 5.427
SNIP: 2.243
open access Open Access

American Association for Cancer Research

Quality:  
High
CiteRatio: 8.7
SJR: 2.273
SNIP: 1.157

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

4.988

12% from 2018

Impact factor for Breast Cancer Research from 2016 - 2019
Year Value
2019 4.988
2018 5.676
2017 6.142
2016 6.345
graph view Graph view
table view Table view

8.8

4% from 2019

CiteRatio for Breast Cancer Research from 2016 - 2020
Year Value
2020 8.8
2019 8.5
2018 10.1
2017 11.5
2016 10.0
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 12% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 4% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

2.378

1% from 2019

SJR for Breast Cancer Research from 2016 - 2020
Year Value
2020 2.378
2019 2.407
2018 2.874
2017 3.026
2016 2.931
graph view Graph view
table view Table view

1.466

6% from 2019

SNIP for Breast Cancer Research from 2016 - 2020
Year Value
2020 1.466
2019 1.552
2018 1.804
2017 1.764
2016 1.601
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has decreased by 1% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has decreased by 6% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Breast Cancer Research

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

Breast Cancer Research

Approved by publishing and review experts on SciSpace, this template is built as per for Breast Cancer Research formatting guidelines as mentioned in Springer author instructions. The current version was created on and has been used by 666 authors to write and format their manuscripts to this journal.

i
Last updated on
08 Jun 2020
i
ISSN
1606-8610
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
White faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Citation Type
Numbered
[25]
i
Bibliography Example
Blonder, G.E., Tinkham, M., Klapwijk, T.M.: Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B 25(7), 4515–4532 (1982)

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1186/BCR2635
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
02 Sep 2010 - Breast Cancer Research

Abstract:

Introduction In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype. Introduction In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype. read more read less

Topics:

Breast cancer (54%)54% related to the paper, Claudin-Low (53%)53% related to the paper
View PDF
1,991 Citations
open accessOpen access Journal Article DOI: 10.1186/BCR2889
Choosing the right cell line for breast cancer research
Deborah L. Holliday1, Valerie Speirs1
12 Aug 2011 - Breast Cancer Research

Abstract:

Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of predictive markers like oestro... Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of predictive markers like oestrogen receptor and human epidermal growth factor receptor 2 (HER2) to a more sophisticated classification comprising luminal A, luminal B, basal-like, HER2-positive and normal subgroups. In the laboratory, breast cancer is often modelled using established cell lines. In the present review we discuss some of the issues surrounding the use of breast cancer cell lines as experimental models, in light of these revised clinical classifications, and put forward suggestions for improving their use in translational breast cancer research. read more read less

Topics:

Breast cancer (65%)65% related to the paper, CA15-3 (61%)61% related to the paper
View PDF
1,276 Citations
open accessOpen access Journal Article DOI: 10.1186/BCR2419
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
29 Oct 2009 - Breast Cancer Research

Abstract:

Introduction Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors o... Introduction Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. Methods Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response. read more read less

Topics:

Cyclin-dependent kinase 6 (62%)62% related to the paper, Cyclin-dependent kinase 4 (61%)61% related to the paper, Cyclin D (61%)61% related to the paper, Cancer (59%)59% related to the paper, Cyclin-dependent kinase (59%)59% related to the paper
View PDF
1,169 Citations
open accessOpen access Journal Article DOI: 10.1186/BCR1982
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.
Christine M. Fillmore1, Charlotte Kuperwasser2, Charlotte Kuperwasser1
26 Mar 2008 - Breast Cancer Research

Abstract:

The phenotypic and functional differences between cells that initiate human breast tumors (cancer stem cells) and those that comprise the tumor bulk are difficult to study using only primary tumor tissue. We embarked on this study hypothesizing that breast cancer cell lines would contain analogous hierarchical differentiation... The phenotypic and functional differences between cells that initiate human breast tumors (cancer stem cells) and those that comprise the tumor bulk are difficult to study using only primary tumor tissue. We embarked on this study hypothesizing that breast cancer cell lines would contain analogous hierarchical differentiation programs to those found in primary breast tumors. Eight human breast cell lines (human mammary epithelial cells, and MCF10A, MCF7, SUM149, SUM159, SUM1315 and MDA.MB.231 cells) were analyzed using flow cytometry for CD44, CD24, and epithelial-specific antigen (ESA) expression. Limiting dilution orthotopic injections were used to evaluate tumor initiation, while serial colony-forming unit, reconstitution and tumorsphere assays were performed to assess self-renewal and differentiation. Pulse-chase bromodeoxyuridine (5-bromo-2-deoxyuridine [BrdU]) labeling was used to examine cell cycle and label-retention of cancer stem cells. Cells were treated with paclitaxol and 5-fluorouracil to test selective resistance to chemotherapy, and gene expression profile after chemotherapy were examined. The percentage of CD44+/CD24- cells within cell lines does not correlate with tumorigenicity, but as few as 100 cells can form tumors when sorted for CD44+/CD24-/low/ESA+. Furthermore, CD44+/CD24-/ESA+ cells can self-renew, reconstitute the parental cell line, retain BrdU label, and preferentially survive chemotherapy. These data validate the use of cancer cell lines as models for the development and testing of novel therapeutics aimed at eradicating cancer stem cells. read more read less

Topics:

Cancer stem cell (68%)68% related to the paper, CD44 (60%)60% related to the paper, Tumor initiation (56%)56% related to the paper, Primary tumor (55%)55% related to the paper, Cell cycle (54%)54% related to the paper
View PDF
1,065 Citations
open accessOpen access Journal Article DOI: 10.1186/BCR1610
CD44 + /CD24 - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis
24 Oct 2006 - Breast Cancer Research

Abstract:

A subpopulation (CD44+/CD24-) of breast cancer cells has been reported to have stem/progenitor cell properties. The aim of this study was to investigate whether this subpopulation of cancer cells has the unique ability to invade, home, and proliferate at sites of metastasis. CD44 and CD24 expression was determined by flow cyt... A subpopulation (CD44+/CD24-) of breast cancer cells has been reported to have stem/progenitor cell properties. The aim of this study was to investigate whether this subpopulation of cancer cells has the unique ability to invade, home, and proliferate at sites of metastasis. CD44 and CD24 expression was determined by flow cytometry. Northern blotting was used to determine the expression of proinvasive and 'bone and lung metastasis signature' genes. A matrigel invasion assay and intracardiac inoculation into nude mice were used to evaluate invasion, and homing and proliferation at sites of metastasis, respectively. Five among 13 breast cancer cell lines examined (MDA-MB-231, MDA-MB-436, Hs578T, SUM1315, and HBL-100) contained a higher percentage (>30%) of CD44+/CD24- cells. Cell lines with high CD44+/CD24- cell numbers express basal/mesenchymal or myoepithelial but not luminal markers. Expression levels of proinvasive genes (IL-1α, IL-6, IL-8, and urokinase plasminogen activator [UPA]) were higher in cell lines with a significant CD44+/CD24- population than in other cell lines. Among the CD44+/CD24--positive cell lines, MDA-MB-231 has the unique property of expressing a broad range of genes that favor bone and lung metastasis. Consistent with previous studies in nude mice, cell lines with CD44+/CD24- subpopulation were more invasive than other cell lines. However, only a subset of CD44+/CD24--positive cell lines was able to home and proliferate in lungs. Breast cancer cells with CD44+/CD24- subpopulation express higher levels of proinvasive genes and have highly invasive properties. However, this phenotype is not sufficient to predict capacity for pulmonary metastasis. read more read less

Topics:

CD44 (59%)59% related to the paper, Cancer stem cell (59%)59% related to the paper, Cancer cell (59%)59% related to the paper, Metastasis (58%)58% related to the paper, Progenitor cell (57%)57% related to the paper
View PDF
969 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Breast Cancer Research.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Breast Cancer Research in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Breast Cancer Research guidelines and auto format it.

2. Do you follow the Breast Cancer Research guidelines?

Yes, the template is compliant with the Breast Cancer Research guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Breast Cancer Research?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Breast Cancer Research citation style.

4. Can I use the Breast Cancer Research templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Breast Cancer Research.

5. Can I use a manuscript in Breast Cancer Research that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Breast Cancer Research that you can download at the end.

6. How long does it usually take you to format my papers in Breast Cancer Research?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Breast Cancer Research.

7. Where can I find the template for the Breast Cancer Research?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Breast Cancer Research's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Breast Cancer Research's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Breast Cancer Research an online tool or is there a desktop version?

SciSpace's Breast Cancer Research is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Breast Cancer Research?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Breast Cancer Research?”

11. What is the output that I would get after using Breast Cancer Research?

After writing your paper autoformatting in Breast Cancer Research, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Breast Cancer Research's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Breast Cancer Research?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Breast Cancer Research. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Breast Cancer Research?

The 5 most common citation types in order of usage for Breast Cancer Research are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Breast Cancer Research?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Breast Cancer Research's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Breast Cancer Research in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Breast Cancer Research Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Breast Cancer Research formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template